Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG

JH. Dalle, A. Balduzzi, P. Bader, A. Pieczonka, I. Yaniv, A. Lankester, M. Bierings, A. Yesilipek, P. Sedlacek, M. Ifversen, P. Svec, J. Toporski, T. Gungor, J. Wachowiak, E. Glogova, U. Poetschger, C. Peters

. 2021 ; 56 (1) : 257-266. [pub] 20200804

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21019501
E-resources Online Full text

NLK Free Medical Journals from 1997 to 1 year ago
Freely Accessible Science Journals from 1997 to 1 year ago
ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1997-01-01
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago

Links

PubMed 32753706
DOI 10.1038/s41409-020-01014-x
Knihovny.cz E-resources

Allogeneic HSCT represents the only potentially curative treatment for very high risk (VHR) ALL. Two consecutive international prospective studies, ALL-SCT-(I)BFM 2003 and 2007 were conducted in 1150 pediatric patients. 569 presented with VHR disease leading to any kind of HSCT. All patients >2 year old were transplanted after TBI-based MAC. The median follow-up was 5 years. 463 patients were transplanted from matched donor (MD) and 106 from mismatched donor (MMD). 214 were in CR1. Stem cell source was unmanipulated BM for 330 patients, unmanipulated PBSC for 135, ex vivo T-cell depleted PBSC for 62 and cord-blood for 26. There were more advanced disease, more ex vivo T-cell depletion, and more chemotherapy based conditioning regimen for patients transplanted from MMD as compared to those transplanted from MSD or MD. Median follow up (reversed Kaplan Meier estimator) was 4.99 years, median follow up of survivals was 4.88, range (0.01-11.72) years. The 4-year CI of extensive cGvHD was 13 ± 2% and 17 ± 4% (p = NS) for the patients transplanted from MD and MMD, respectively. 4-year EFS was statistically better for patients transplanted from MD (60 ± 2% vs. 42 ± 5%, p < 0.001) for the whole cohort. This difference does not exist if considering separately patients treated in the most recent study. There was no difference in 4-year CI of relapse. The 4-year NRM was lower for patients transplanted from MD (9 ± 1% vs. 23 ± 4%, p < 0.001). In multivariate analysis, donor-type appears as a negative risk-factor for OS, EFS, and NRM. This paper demonstrates the impact of donor type on overall results of allogeneic stem cell transplantation for very-high risk pediatric acute lymphoblastic leukemia with worse results when using MMD stem cell source.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019501
003      
CZ-PrNML
005      
20210830101101.0
007      
ta
008      
210728s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41409-020-01014-x $2 doi
035    __
$a (PubMed)32753706
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Dalle, Jean-Hugues $u Department of Pediatric Hemato-Immunology, Hôpital Robert Debré, APHP Nord-Université de Paris, Paris, France. jean-hugues.dalle@aphp.fr
245    14
$a The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG / $c JH. Dalle, A. Balduzzi, P. Bader, A. Pieczonka, I. Yaniv, A. Lankester, M. Bierings, A. Yesilipek, P. Sedlacek, M. Ifversen, P. Svec, J. Toporski, T. Gungor, J. Wachowiak, E. Glogova, U. Poetschger, C. Peters
520    9_
$a Allogeneic HSCT represents the only potentially curative treatment for very high risk (VHR) ALL. Two consecutive international prospective studies, ALL-SCT-(I)BFM 2003 and 2007 were conducted in 1150 pediatric patients. 569 presented with VHR disease leading to any kind of HSCT. All patients >2 year old were transplanted after TBI-based MAC. The median follow-up was 5 years. 463 patients were transplanted from matched donor (MD) and 106 from mismatched donor (MMD). 214 were in CR1. Stem cell source was unmanipulated BM for 330 patients, unmanipulated PBSC for 135, ex vivo T-cell depleted PBSC for 62 and cord-blood for 26. There were more advanced disease, more ex vivo T-cell depletion, and more chemotherapy based conditioning regimen for patients transplanted from MMD as compared to those transplanted from MSD or MD. Median follow up (reversed Kaplan Meier estimator) was 4.99 years, median follow up of survivals was 4.88, range (0.01-11.72) years. The 4-year CI of extensive cGvHD was 13 ± 2% and 17 ± 4% (p = NS) for the patients transplanted from MD and MMD, respectively. 4-year EFS was statistically better for patients transplanted from MD (60 ± 2% vs. 42 ± 5%, p < 0.001) for the whole cohort. This difference does not exist if considering separately patients treated in the most recent study. There was no difference in 4-year CI of relapse. The 4-year NRM was lower for patients transplanted from MD (9 ± 1% vs. 23 ± 4%, p < 0.001). In multivariate analysis, donor-type appears as a negative risk-factor for OS, EFS, and NRM. This paper demonstrates the impact of donor type on overall results of allogeneic stem cell transplantation for very-high risk pediatric acute lymphoblastic leukemia with worse results when using MMD stem cell source.
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    12
$a nemoc štěpu proti hostiteli $7 D006086
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    12
$a akutní lymfatická leukemie $x terapie $7 D054198
650    _2
$a prospektivní studie $7 D011446
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a dárci tkání $7 D014019
650    _2
$a příprava pacienta k transplantaci $7 D019172
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Balduzzi, Adriana $u Clinica Pediatrica, Università degli Studi di Milano Bicocca, Fondazione MBBM/Ospedale San Gerardo, Monza, Italy
700    1_
$a Bader, Peter $u Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
700    1_
$a Pieczonka, Anna $u Poznan University of Medical Sciences, Depratment of Pediatric Oncology, Hematology and HSCT, Poznan, Poland
700    1_
$a Yaniv, Isaac $u The Raina Zaizov Pediatric Hematology Oncology Division, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
700    1_
$a Lankester, Arjan $u Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands
700    1_
$a Bierings, Marc $u Department of Hematology, University Hospital of Children, Utrecht, the Netherlands
700    1_
$a Yesilipek, Akif $u Pediatric Stem Cell Transplantation Unit, Medical Park Antalya Hospital, Antalya, Turkey
700    1_
$a Sedlacek, Petr $u Department of Paediatric Haematology and Oncology, University Hospital Motol, Prague, Czech Republic
700    1_
$a Ifversen, Marianne $u Rigshospitalet, Paediatric Clinic II, Copenhagen, Denmark
700    1_
$a Svec, Peter $u Department of Paediatric Haematology and Oncology, Haematopoietic Stem Cell Transplantation Unit, Comenius University Children's Hospital, Bratislava, Slovakia
700    1_
$a Toporski, Jacek $u Department of Hematology, Skanes University Hopsital, Lund, Sweden
700    1_
$a Gungor, Taifun $u Pediatric Stem Cell Transplantation, UZH, University of Zurich, Zurich, Switzerland
700    1_
$a Wachowiak, Jacek $u Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands
700    1_
$a Glogova, Evgenia $u St Anna Children's Hospital, Universitätsklinik für Kinder- und Jugendheilkunde, Medizinische Universität Wien, Vienna, Austria
700    1_
$a Poetschger, Ulrike $u St Anna Children's Hospital, Universitätsklinik für Kinder- und Jugendheilkunde, Medizinische Universität Wien, Vienna, Austria
700    1_
$a Peters, Christina $u St Anna Children's Hospital, Universitätsklinik für Kinder- und Jugendheilkunde, Medizinische Universität Wien, Vienna, Austria
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 56, č. 1 (2021), s. 257-266
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32753706 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101101 $b ABA008
999    __
$a ok $b bmc $g 1690347 $s 1139947
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 56 $c 1 $d 257-266 $e 20200804 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20210728
Back

Find record

Citation metrics

Archiving options